Dafna Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Dafna Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $146,965 - $218,330	-3,500 Reduced 3.77%	89,387 $5.25 Million
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $50,401 - $82,219	-1,813 Reduced 1.91%	92,887 $4.05 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $762,343 - $1.04 Million	21,100 Added 28.67%	94,700 $3.42 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $82,540 - $197,240	2,000 Added 2.79%	73,600 $3.33 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $476,000 - $693,600	-8,000 Reduced 10.05%	71,600 $5 Million

Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $1.45 Million - $3.27 Million	36,900 Added 86.42%	79,600 $5.34 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $3.24 Million - $6.45 Million	42,700 New	42,700 $3.51 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $2.48 Million - $3.66 Million	-21,893 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $1.46 Million - $2.43 Million	-20,209 Reduced 48.0%	21,893 $2.5 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $2.94 Million - $4.89 Million	42,102 New	42,102 $3.24 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.